Mesenchymal Stem Cell Identification via Fluorescent Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for identifying specific cell markers to distinguish rare cell sub-populations, such as mesenchymal stem cells, from the general population of mesenchymal stromal cells derived from oral mucosa, and for therapeutic use of enriched subpopulations of mesenchymal stem cells.
Innovation Solution
A method for identifying a multipotent mesenchymal stem cell subpopulation by contacting a population of cells with probes capable of identifying specific markers such as UBE2S, ASPM, PRC1, and others, and a pharmaceutical composition comprising an enriched mesenchymal stem cell subpopulation with above a predetermined threshold expression of these markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional mesenchymal stromal cell cultures are used, then ease of access and culturing is improved, but the ability to distinguish and isolate rare mesenchymal stem cell subpopulations deteriorates due to cellular heterogeneity
Solution Approach 1:
The patent employs fluorescent probes that bind to specific cellular markers (such as ALDH1, CD73, CD90, CD105) to differentiate mesenchymal stem cells from other stromal cells. The fluorescent labeling enables visual identification and sorting of rare stem cell subpopulations within the heterogeneous culture, resolving the measurement precision issue while maintaining ease of operation through established culturing methods.
Solution Approach 2:
The patent introduces specific molecular markers and fluorescent probes as intermediaries to bridge the gap between conventional culturing methods and precise cell identification. These markers serve as mediators that enable the detection and isolation of rare mesenchymal stem cells without requiring changes to the underlying culturing protocols, thus maintaining ease of operation while improving measurement precision.
2Productivity
If bulk mesenchymal stromal cell populations are used for therapy, then availability and ease of use is improved, but therapeutic efficacy deteriorates due to low proportion of actual stem cells
Solution Approach 1:
The patent extracts and isolates the rare mesenchymal stem cell subpopulation from the bulk heterogeneous stromal cell culture using fluorescent-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS) based on specific marker expression. This extraction process enriches the therapeutic product with actual stem cells (increasing reliability/efficacy) while maintaining productivity through efficient sorting protocols that can process large cell numbers.
Solution Approach 2:
The patent changes the compositional parameter of the cell therapy product by selecting for cells with specific marker profiles (e.g., ALDH1high, CD73+, CD90+, CD105+). This parameter change transforms the bulk heterogeneous population into an enriched stem cell subpopulation with enhanced therapeutic efficacy, while the sorting process maintains high productivity through automated flow cytometry platforms.
3Manufacturing precision
If specific cell markers are used for identification, then the ability to isolate pure stem cell subpopulations is improved, but the complexity of the identification process increases
Solution Approach 1:
The patent employs a panel of well-established, universally applicable cell surface markers (CD73, CD90, CD105) and intracellular markers (ALDH1) that can be detected using standard flow cytometry or immunohistochemistry protocols. These markers serve multiple functions: identifying stem cells, enabling sorting, and validating purity. The use of conventional reagents and methods maintains procedural simplicity while achieving high manufacturing precision through the specificity of the marker panel.
Data Source
AI summary
A method for identification of a multipotent mesenchymal stem cell subpopulation, among a heterogenic population of gastrointestinal tract mucosa mesenchymal stromal cells, is provided. Further provided is a kit including a probe for identification or isolation of gastrointestinal tract mucosa mesenchymal stem cells, and a pharmaceutical composition including enriched or isolated mesenchymal stem cell from the gastrointestinal tract mucosa, for treating an individual suffering from a disorder or a disease.